Blood-based liver evaluation test that uses
10 biomarkers and advanced technology to determine
the condition the liver
- What is LIVERFASt™
- How it works
- What does it measure
- Clinical Validation
- Integration and Usability
What is LIVERFASt™?
LIVERFASt™ provides a score from 0.00 to 1.00 and its estimated grade or stage, similar to
the histopathological scoring of the liver (based on the liver biopsy classification).
How it Works
Physician prescribes
LIVERFASt™
Lab analyzes
10 biomarkers from
1 blood draw
Biomarker values plus age,
height, weight, gender, are
entered into the platform
LIVERFASt™ results
are available
immediately
Physician prescribes
LIVERFASt™
Lab analyzes
10 biomarkers from
1 blood draw
Biomarker values plus age,
height, weight, gender, are
entered into the platform
LIVERFASt™ results
are available
immediately
What does LIVERFASt™ Measure?
LIVERFASt™ takes inputs from 10 biomarkers and patient anthropometrics to generate a
score from 0.00 to 1.00 that corresponds to the histopathological staging of a liver biopsy.
Fibrosis
STAGE
INTERPRETATION
FO
No fibrosis
F1
Mild fibrosis
F2
Advanced fibrosis
F1
Significant fibrosis
F4
Severe fibrosis/cirrhosis
Activity
STAGE
INTERPRETATION
aO
No activity
a1
Mild activity
a2
Moderate activity
a1
Marked activity
a4
Severe activity
Steatosis
STAGE
INTERPRETATION
sO
No steatosis (<5%)
s1
Mild steatosis(5-33%)
s2
Moderate steatosis(34-66%)
s3
Marked steatosis (≥ 67%)
Clinical Validation
LIVERFASt™ is clinically validated against different cohorts, and can
be used to test patients wit different comorbidities
LIVIRFASt has high clinical performance for Fibrosis & Activity
LIVIRFASt Activity Test performance
MASLD population(n=223)
0.65
LIVIRFASt Fibrosis Test performance
MASLD population(n=223)
0.75
Negative Predictive Value
0.88
0.71
The concordance for cirrhosis with Liver Biopsy (n=452)
LIVERFASt
LSM
FIB-4
67/95(71%)
51/95(54%)
45/95(47%)
Integration and Usability
LIVERFASt™ seamlessly integrates into any clinical or healthcare setting, enhancing liver health screening workflows without disrupting existing systems